The 12-week human clinical trial began in early June 2024 and set out to investigate if, through these mechanisms of action, ...
Most patients should not stop taking GLP-1 receptor agonists prior to elective surgery, according to updated guidance from several medical societies, including the American Society of ...
Most patients may continue to safely take glucagon-like peptide-1 (GLP-1) receptor agonists as prescribed before undergoing ...
Analysis of real-world data compared patients on GIMOTI (n=51) to Oral Metoclopramide (n=41), both taking GLP-1s, showing ...
News and talk of GLP-1 drugs are everywhere these days—from their smash success in treating Type 2 diabetes and obesity to ...
As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim ...
A large retrospective study, the first of its kind, reported reduced rates of EO-CRC in patients younger than 50 years of age ...
When food enters the digestive system, specialized cells in the small intestine release GLP-1, initiating a cascade of ...
While all state Medicaid programs cover GLP-1 agonists for type 2 diabetes, it’s much less common for them to cover the drugs ...
Among privately insured patients, there was a doubling in the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as ...